GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zura Bio Ltd (NAS:ZURA) » Definitions » Cyclically Adjusted FCF per Share

ZURA (Zura Bio) Cyclically Adjusted FCF per Share : $0.00 (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Zura Bio Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Zura Bio's adjusted free cash flow per share data for the fiscal year that ended in Dec. 2024 was $-0.442. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $0.00 for the trailing ten years ended in Dec. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2025-05-11), Zura Bio's current stock price is $ 1.21. Zura Bio's Cyclically Adjusted FCF per Share for the fiscal year that ended in Dec. 2024 was $0.00. Zura Bio's Cyclically Adjusted Price-to-FCF of today is .


Zura Bio Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Zura Bio's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zura Bio Cyclically Adjusted FCF per Share Chart

Zura Bio Annual Data
Trend Mar22 Dec23 Dec24
Cyclically Adjusted FCF per Share
- - -

Zura Bio Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Zura Bio's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Zura Bio's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zura Bio's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zura Bio's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Zura Bio's Cyclically Adjusted Price-to-FCF falls into.


;
;

Zura Bio Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Zura Bio's adjusted Free Cash Flow per Share data for the fiscal year that ended in Dec. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.442/133.1571*133.1571
=-0.442

Current CPI (Dec. 2024) = 133.1571.

Zura Bio does not have a history long enough to calculate Cyclically Adjusted FCF per Share. Therefore GuruFocus does not calculate it.


Zura Bio  (NAS:ZURA) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Zura Bio Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Zura Bio's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Zura Bio Business Description

Industry
Traded in Other Exchanges
N/A
Address
1489 W. Warm Springs Road, Suite 110, Henderson, NV, USA, 89014
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.
Executives
Parvinder Thiara director, 10 percent owner C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Someit Sidhu director C/O MAPLES CORPORATE SERVICES LIMITED, PO BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-11
Ploos Van Amstel Arnout director C/O MAPLES CORPORATE SERVICES LIMITED, PO BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-11
Amit Munshi director C/O EPIRUS BIOPHARMACEUTICALS, INC., 699 BOYLSTON STREET, 8TH FLOOR, BOSTON MA 02116
Michael Howell officer: SVP, Translational Medicine 4225 EXECUTIVE SQUARE, SUITE 600, LA JOLLA CA 92037
Garry Arthur Neil director 555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Ewon Comfortech Co., Ltd. 10 percent owner 8, CHEOMDAN 1-RO, JEONGUP-SI, JEONLABUK-DO M5 320836
Chris Kim 10 percent owner 6 CENTERPOINTE DR., #625, LA PALMA CA 90623
Hana Immunotherapeutics Llc 10 percent owner 6 CENTERPOINTE DR., #625, LA PALMA CA 90623
Theresa Lowry officer: EVP and CHRO 3629 VILLA TERRACE, SAN DIEGO CA 92104
Gary Whale officer: EVP and CTO 2 THE BEACHES, SHIPLAKE, HENLEY-ON-THAMES, OXFORDSHIRE X0 RG9 3BT
Kimberly Ann Davis officer: Secretary and General Counsel C/O ZURA BIO INC., 4225 EXECUTIVE SQUARE, SUITE 600, LA JOLLA CA 92037
Graham Neil Murray Hamilton director 33 MT. GREEN RD, CROTON ON HUDSON, NEW YORK NY 10520
Sandeep Chidambar Kulkarni director 92 MORNINGSIDE AVE., APT 7E, NEW YORK NM 10027
Pfizer Inc 10 percent owner 66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192